Blueprint Medicines at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Blueprint Medicines is at ASH 2026 in New Orleans. Blueprint Medicines supports symposia devoted to systemic mastocytosis. Its program runs from diagnostic criteria and risk grouping to treatment choices for indolent and advanced forms of the disease.
| Organization | ASH 2026 Attendance |
|---|---|
Blueprint Medicines Cambridge, MA | |
Precision therapy company, now part of Sanofi, known for avapritinib for systemic mastocytosis. | Symposium Fri Dec 11 7:00pm–10:00pm Clinical Turning Points: Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis Recognizing the full symptom burden of non-advanced systemic mastocytosis, judging disease control, and deciding when to escalate to disease-directed therapy. Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. |
Instantly find 20 buyers from Blueprint Medicines
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction